Facebook-f X-twitter Linkedin-in Instagram Youtube

Landing Page

All Content

Ares Strategic Mining Nabs $11M for U.S. Fluorspar & Gallium Revival

Big funding. Bigger plans. Ares Strategic Mining is locking in the support it needs to become America’s only source for fluorspar (and likely gallium, too). With major moves underway at...

Gallium: A Unicorn Critical Mineral

Gallium is one of the most strategically important metals you've probably not heard of. Used in semiconductors, LEDs, 5G infrastructure, and advanced defense systems, gallium nitride technology is essential to...
Agentic AI

Agentic AI: Have You Heard of It?

Venture capitals are heavily backing agentic AI startups - autonomous software “agents” set to transform productivity tools and SaaS workflows....

Ioneer Quadruples Reserves, Doubles Costs

Ioneer has quadrupled reserves at its Rhyolite Ridge lithium-boron project, extending the project's mine life to nearly a century....

‘Unusually Cautious’: Biotech Dealmakers Hit the Brakes

After a quiet period for biotech M&A, dealmakers started 2025 with renewed optimism. Many expected a rebound in billion-dollar transactions, bolstered by early momentum like Johnson & Johnson’s $14.6 billion...

EV Market Outpaces Hybrids with a 29% YTD surge

EV sales are accelerating globally, with China and the EU driving most of the momentum. While geopolitical tensions persist, policy shifts and domestic incentives are pushing the industry forward, though...

U.S. Fast-Tracks 10 More Mining Projects

The Trump administration has added 10 new mining projects to the FAST-41 permitting initiative, intensifying efforts to boost domestic production of critical minerals like copper, palladium, and uranium....

IBM Charts New AI Course with Major U.S. Investment

IBM is making a decisive play in the enterprise AI market with new integration tools that help clients manage diverse AI systems. Backed by a $150 billion U.S. investment plan...

GSK Q1 Strength Signals Tariff Resilience

British pharma heavyweight GSK reports a strong start to 2025 with earnings exceeding forecasts and reaffirms its growth outlook—positioning itself as a stable force even as potential U.S. pharmaceutical tariffs...
en_USEnglish
de_DEGerman en_USEnglish